Summarized by Masters of Longevity from Cambrian Bio.
Two Phase 1 studies found metabolic improvements and altered lipid and energy measures.
Key Takeaways
- ATX-304 showed metabolic improvements in adults with obesity and prediabetes.
- Findings were reported from two Phase 1 clinical studies at ObesityWeek.
- Phase 2 trials are planned but efficacy in larger populations remains unproven.
